The
tumor lysis syndrome (TLS) commonly occurs in the
lymphoproliferative disorder, either spontaneously or in response to
therapy. TLS is uncommon in
multiple myeloma. However, with the use of
bortezomib in the
treatment of
multiple myeloma, cases of TLS have been reported. We
report here threepatients
who presented with TLS after the
administration of
bortezomib. Two of them presented mild symptoms and recovered with hydration only. However,
death of the other
patient was associated with TLS. We should monitor
patients who had high
tumor burden, especially in early phase of
bortezomib therapy and appropriate prophylaxis for high
risk patient is also needed.